Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVE1642 plus fulvestrant in postmenopausal women with advanced hormone-dependent breast cancer
2008-000810-54Phase 2Completed
- Sponsor
- Sanofi
- Start
- May 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer comparing AVE1642 + fulvestrant with Fulvestrant (2 arms). Primary endpoint: Clinical benefit rate. Started May 2008; status: completed.
02
Drugs
veligrotugfulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2008-000810-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000810-54.